Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
93.14 CHF | +0.08% | +3.84% | +9.85% |
May. 13 | Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales | DJ |
May. 10 | Novartis’ Scemblix Gets Third US FDA Breakthrough Therapy Designation | MT |
Sales 2024 * | 48.96B 44.42B | Sales 2025 * | 50.79B 46.08B | Capitalization | 209B 190B |
---|---|---|---|---|---|
Net income 2024 * | 10.5B 9.53B | Net income 2025 * | 12.07B 10.95B | EV / Sales 2024 * | 4.54 x |
Net Debt 2024 * | 12.88B 11.68B | Net Debt 2025 * | 11.28B 10.23B | EV / Sales 2025 * | 4.34 x |
P/E ratio 2024 * |
20
x | P/E ratio 2025 * |
17.2
x | Employees | 76,057 |
Yield 2024 * |
3.52% | Yield 2025 * |
3.66% | Free-Float | 85.22% |
Latest transcript on Novartis AG
1 day | -0.20% | ||
1 week | +3.42% | ||
Current month | +4.27% | ||
1 month | +7.34% | ||
3 months | +5.75% | ||
6 months | +9.80% | ||
Current year | +9.40% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 04-12-31 | |
Director of Finance/CFO | 59 | 02-12-31 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 22-05-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 12-12-31 |
Simon Moroney
BRD | Director/Board Member | 65 | 20-02-27 |
Chairman | 68 | 12-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
10.40% | 121 M€ | -.--% | - | |
5.57% | 17 M€ | +6.46% | - | |
4.12% | 88 M€ | +10.37% | - | |
3.79% | 2 M€ | -25.75% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 93.24 | +0.18% | 770 486 |
24-05-13 | 93.07 | +0.81% | 3,892,615 |
24-05-10 | 92.32 | +1.97% | 3,233,804 |
24-05-08 | 90.54 | +0.85% | 2,553,649 |
24-05-07 | 89.78 | +1.91% | 2,442,038 |
Delayed Quote Swiss Exchange, May 14, 2024 at 05:18 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.40% | 209B | |
+29.98% | 682B | |
+31.77% | 586B | |
-3.52% | 364B | |
+18.59% | 327B | |
+4.07% | 285B | |
+16.51% | 240B | |
-8.79% | 203B | |
+7.09% | 165B | |
-1.22% | 161B |
- Stock Market
- Equities
- NOVN Stock